While none of these observations are especially surprising given what we already know about Medicare coverage pathways and obesity treatment, the form does provide some useful confirmation of how the program is expected to operate in practice
Over time, as real-world evidence accumulates and long-term economic benefits are revealed, GLP-1 therapies could potentially become a mainstay in OSA treatment
A 2024 study in Obesity found that exercise combined with semaglutide preserved 93% of lean mass compared to 80% in the drug-only group
Wang J, Yi Y, Xiao Y, Dong L, Liang L, Teng L, Ying JM, Lu T, Liu Y, Guan Y, Pang J, Zhou L, Lu J, Zhang Z, Liu X, Liang X, Zeng X, Yi X, Zhou W, Xia X, Yang L, Zhang J, Kopetz S , Futreal PA, Wu H, Liang Z